Mezzan Holding Company Kscc — Merger or Acquisition (August 2019)

5 slides from Mezzan Holding Company Kscc's merger presentation, Aug 7, 2019

Slide 1: Investor Briefing: Mezzan Holding's 67% Acquisition of KSPICO
August 7, 2019 Investor Briefing Mezzan Holding’s 67% Acquisition of KSPICO Transaction Overview Description of Target Strategic Rationale 1
Slide 2: Transaction Overview
TransactionOverview 67% Majority Mezzan Holding has acquired a 67% stake in Kuwait Saudi Pharmaceutical Industries Company KSCC (KSPICO), granting it majority Board seats and effective control. Purchased through debt Valuation at P/E of 15.6x (2018) KSPICO D/E < 20% The only licensed pharmaceutical
Slide 3: Exclusive position in Pharma manufacturing sector
StrategicRationale Exclusive position in Pharma manufacturing sector Rationale Exclusivity Strength Synergy Growth KSPICO is the only Reinforces our presence in Creates synergies Preferential treatment in manufacturer of pharma healthcare, our relationship with warehousing, logistics, pricing Kuwait
Slide 4: Strength, growth and exclusivity
StrategicRationale Strength, growth and exclusivity KSPICO Strengths Growth Opportunities Recently expanded capacities, Increase participation in local tenders (100+ KSPICO especially in LVP products registered but not active) LVP line enjoys c.80% market Grow market share locally and regionally sha
Slide 5: A new market leader is born in Kuwait's healthcare sector
A new market leader is born in Kuwait’s healthcare sector 5